Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
← catalyst calendarNCT07282795 · readout in 918 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
670estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-01 | estimated | When the study began enrolling |
| Primary completion | 2029-02-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Influenza Immunization
- Healthy Volunteers
Intervention
- Biological: Efluelda® Pre-filled syringe
Primary outcomes
what the primary-completion date above is the date OFOccurrence of solicited injected site reactions.
measured Up to 7 days after vaccination
Occurrence of solicited systemic reactions
measured Up to 7 days after vaccination
Occurrence of unsolicited Adverse Events (AE)
measured From vaccination to Visit 2 (up to approximately 42 days)
Occurrence of unsolicited Adverse Drug Reactions (ADR)
measured From vaccination to Visit 2 (up to approximately 42 days)
Occurrence of unexpected Adverse Events (AE)
measured From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of unexpected Adverse Drug Reactions (ADR)
measured From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of Serious Adverse Events (SAE)
measured From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of unexpected Serious Adverse Drug Reactions (SADR)
measured From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of Adverse Event of Special Interest (AESI)
measured From vaccination to participant's last contact (up to approximately 42 days)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed